Abstract
Currently a third drug from the gliptin group is marketed in the Czech republic - saxagliptin (Onglyza, 5mg tablets). It is indicated in adjuvant therapy as part of a combination of two drugs and is added to diabetes monotherapywith metformin, sulphonylurea derivatives, or a thiazolidinedione.